Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC16A3 | O15427 | 5/20 | 0.75 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 3/20 | 0.50 |
| ▸ | CA12 | O43570 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA4 | P22748 | 2/20 | 0.50 |
| ▸ | CA6 | P23280 | 2/20 | 0.50 |
| ▸ | CA5A | P35218 | 2/20 | 0.50 |
| ▸ | CA7 | P43166 | 2/20 | 0.50 |
| ▸ | CA9 | Q16790 | 2/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.50 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.50 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.50 |
| ▸ | SLC16A1 | P53985 | 2/20 | 0.50 |
| ▸ | CA3 | P07451 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15138692 | 0.88 | SLC16A3 (0.81) | SLC16A3KDM4EALDH1A1MAOBCA12 | |
| SCHEMBL18493220 | 0.88 | SLC16A3 (0.81) | SLC16A3KDM4EALDH1A1MAOBCA12 | |
| SCHEMBL16397648 | 0.87 | SLC16A3 (0.79) | SLC16A3KDM4EALDH1A1MAOBCA12 | |
| SCHEMBL17701048 | 0.86 | SLC16A3 (1.00) | SLC16A3KDM4EALDH1A1LMNARAB9A | |
| SCHEMBL25810858 | 0.83 | NPC1 (0.55) | SLC16A3KDM4ERAB9AMTHFD2MAPT | |
| SCHEMBL15065831 | 0.82 | SLC16A3 (0.64) | SLC16A3KDM4EALDH1A1LMNAMAOB | |
| SCHEMBL27263233 | 0.81 | DRD2 (0.53) | SLC16A3KDM4EALDH1A1LMNARAB9A | |
| SCHEMBL16312153 | 0.79 | SLC16A3 (0.63) | SLC16A3KDM4EALDH1A1MAOBCA12 | |
| SCHEMBL10434168 | 0.79 | SLC16A3 (0.66) | SLC16A3KDM4EALDH1A1MAOBHPGD | |
| SCHEMBL16674787 | 0.78 | SLC16A3 (0.62) | SLC16A3KDM4EALDH1A1MAOBCA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4705297-A1 | SMALL MOLECULE THERAPY FOR DUCHENNE MUSCULAR DYSTROPHY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-03-11 | — | — | EP | disclosed |
| WO-2024229205-A1 | SMALL MOLECULE THERAPY FOR DUCHENNE MUSCULAR DYSTROPHY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-11-07 | — | — | WO | disclosed |
| US-7569337-B2 | Labeling brain tissues in vivo or in vitro; 3-Benzothiazol-2-yl-7-[4-(2-fluoro-ethyl)-piperazin-1-yl]-chromen-2-one; diagnosis, monitoring the effectiveness of a therapeutic treatment and detecting histopathological hallmarks of Alzheimer's disease | NOVARTIS AG (CH) | 2009-08-04 | — | — | US | disclosed |
| EP-1483262-B1 | COUMARINES USEFUL AS BIOMARKERS | NOVARTIS AG (CH) | 2007-11-14 | — | — | EP | disclosed |
| US-20050169837-A1 | Coumarines useful as biomarkers | NOVARTIS AG (CH) | 2005-08-04 | — | — | US | disclosed |
| EP-1483262-A1 | COUMARINES USEFUL AS BIOMARKERS | Novartis AG (CH) | 2004-12-08 | — | — | EP | disclosed |
| WO-2003074519-A1 | COUMARINES USEFUL AS BIOMARKERS | NOVARTIS AG (CH) | 2003-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050169837-A1 | Coumarines useful as biomarkers | CCNB1, CBR1, CYP1A1 | SLC16A3 2868/4885KDM4E 2497/4885ALDH1A1 86/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.